CHRONULAC Drug Patent Profile
✉ Email this page to a colleague
When do Chronulac patents expire, and what generic alternatives are available?
Chronulac is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in CHRONULAC is lactulose. There are twenty drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the lactulose profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Chronulac
A generic version of CHRONULAC was approved as lactulose by HIKMA on July 3rd, 1995.
Summary for CHRONULAC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 28 |
| Patent Applications: | 3,636 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | CHRONULAC at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for CHRONULAC
US Patents and Regulatory Information for CHRONULAC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | CHRONULAC | lactulose | SOLUTION;ORAL | 017884-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
